{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"7.2","upperLimit":"29.2","value":"9.76"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"19"}],"units":"Participants"}],"description":"OS based on the Kaplan-Meier method is defined as the time from study entry to death or censored at date last known alive.","dispersionType":"80% Confidence Interval","groups":[{"description":"Subjects will receive durvalumab and tremelimumab both via intravenous infusion once per day for every 28 day cycles (+ 7 days). Participants will receive tremelimumab for up to 4 cycles (4 doses). Beginning with cycle 5 day 1, subjects will continue to receive durvalumab alone, until clinical or radiological progression.\n\nTremelimumab: Tremelimumab blocks a receptor on immune cells that normally suppresses immune attack.\n\nDurvalumab: Durvalumab is a drug that blocks a protein often produced by cancer cells or surrounding cells to suppress immune cells from attacking cancer cells.","id":"OG000","title":"Tremelimumab + Durvalumab"}],"paramType":"MEDIAN","populationDescription":"The analysis population is comprised of eligible and treated patients.","reportingStatus":"POSTED","timeFrame":"OS is assessed from date of registration until date of death on-treatment or during follow-up. Survival data collection in long-term follow-up every 3-4 months. Median follow-up for survival is of 27.33 months with range (0.76 months - 50.40 months).","title":"Median Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"months"}